What is the history of Pachyonychia Congenita?

Pachyonychia Congenita was first clinically characterized in 1906 by Jadassohn and Lewandowsky, who identified the condition's hallmark nail thickening and palmoplantar keratoderma. Since then, the understanding of Pachyonychia Congenita has evolved from a purely clinical description of symptoms to a precise molecular diagnosis involving mutations in keratin genes.

When was Pachyonychia Congenita first described?

The medical history of Pachyonychia Congenita began in 1906 when Josef Jadassohn and Felix Lewandowsky described a patient with thickened nails, oral leukokeratosis, and palmoplantar hyperkeratosis. Initially, the condition was defined by these visible clinical features, but early researchers often struggled to distinguish between different subtypes, leading to historical confusion regarding the severity and genetic underpinnings of Pachyonychia Congenita.

How has our understanding of the genetics changed?

For most of the 20th century, Pachyonychia Congenita was diagnosed solely through physical examination. The landscape shifted dramatically in the 1990s when researchers identified that the condition is caused by dominant mutations in five specific keratin genes: KRT6A, KRT6B, KRT6C, KRT16, and KRT17. This discovery allowed for definitive genetic testing, moving the field away from subjective observation toward precise molecular classification.

What are the major milestones in research and advocacy?

The evolution of Pachyonychia Congenita research is marked by several key developments:

• 1906: First clinical description of Pachyonychia Congenita by Jadassohn and Lewandowsky.


• 1995: Discovery of the keratin gene mutations that cause the disease.


• 2004: Establishment of the International Pachyonychia Congenita Research Registry (IPCRR), which standardized data collection for patients worldwide.


• Modern Era: Transition toward personalized medicine, including experimental siRNA therapies aimed at silencing the mutant keratin genes.

How has patient advocacy shaped the field?

The establishment of patient-led organizations has been transformative for those living with Pachyonychia Congenita. By centralizing data and funding, the community has accelerated clinical trials and fostered global collaboration. Today, platforms like DiseaseMaps.org help connect the 4 community members registered with us, ensuring that no patient feels isolated in their journey with this rare condition.

Next steps

• Consult a dermatologist or geneticist to confirm your diagnosis through molecular testing.


• Join the International Pachyonychia Congenita Research Registry (IPCRR) to contribute to global research efforts.


• Connect with the Pachyonychia Congenita community at DiseaseMaps.org to share experiences and coping strategies.

Medical disclaimer: This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of a qualified healthcare provider with any questions regarding a medical condition.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Pachyonychia Congenita.


• Online Mendelian Inheritance in Man (OMIM): Entry #167200 (Pachyonychia Congenita).


• Orphanet: Rare Disease Database (ORPHA:670).


• Pachyonychia Congenita Project (PC Project): Patient advocacy and research foundation.